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INTRODUCTION
Intensity-modulated radiation therapy (IMRT) has been used to provide highly conformal dose distribution to irregular targets. A major and unique characteristic of IMRT is that each field is composed of many subfields or segments which are delivered in sequence, enabling dose distribution to be concentrated on the planning target volume (PTV) while sparing surrounding normal tissues.
The complex segments are calculated using inverse planning. Various commercial treatment planning systems with different optimization methods in inverse planning are available. [1] [2] [3] [4] [5] [6] One optimization method is direct aperture optimization. [2] [3] [4] [5] [6] In this technique, a set of deliverable apertures is included in the optimization, wherein the optimization parameters include aperture shapes, weights, or both. In twostep IMRT optimization, in contrast, each field is divided into a grid of beamlets, the weights of which are then optimized. 1) The optimization provides an ideal intensity map, and the ideal beamlet intensities are then segmented into segments deliverable by the multileaf collimator (MLC). This information is then used to calculate final dose. Therefore the use of small segments increases the deliverable MLC patterns, which potentially improves the final dose distribution. With regard to direct machine parameter optimization (DMPO) available within the Pinnacle 3 treatment planning system, Worthy et al. reported that a minimum segment area of 8 cm 2 is optimal. 6) Regarding two-step optimization, however, no quantitative analysis of the effects of minimum segment size on planning quality, including PTV coverage and hot spots in organs at risk, has not been reported.
Although the use of small segments might improve dose distribution in the treatment planning system, it become difficult to assure the accuracy of beam delivery. [7] [8] [9] [10] [11] [12] In addition, as the number of small segments increases, monitor unit (MU) increases, which could result in longer treatment times and subsequently to intrafractional patient movement.
Here, we investigated the optimum minimum segment size (MSS) in two-step optimization with regard to planning quality. Further, we also conducted composite verifications by various MSS plans to evaluate dosimetric accuracy.
MATERIALS AND METHODS
We analyzed five consecutive prostate cancer patients who received step and shoot IMRT in our hospital. The XiO ver. 4.33.2 (CMS, St Louis, MO) treatment planning system was used in this study. For beam delivery, an Oncor Impression Plus (Siemens Medical Solutions, Erlangen, Germany) equipped with an Optifocus MLC (41 pairs of leaves, with the central leaves having a width of 1.0 cm) were used with a dose rate of 300 MU/min.
Beam setup in treatment planning and delivery
The clinical target volume (CTV) was generated for the prostate and a part of the seminal vesicle by adding a 10-mm margin to the anterior, superior, inferior, left, and right directions of the prostate and 6-mm margin to the posterior direction. The overlapping region of the CTV and rectum was then subtracted, and the resulting volume was defined as the PTV. A 5-field coplanar treatment plan with beam angles of 45°, 105°, 180°, 255°, 315° was generated with a 10 MV photon beam for each patient.
IMRT optimization and plan evaluation
The XiO IMRT treatment planning system uses two-step optimization. The optimization process can be divided into two stages. During the first stage, the optimizer uses inverse planning objectives, anatomy contours, and beamlets to produce ideal intensity maps and ideal doses. By "ideal", it is meant beamlet intensities and doses that might be delivered if the realities of treatment delivery could be ignored. In the second stage, ideal beamlet intensities are converted to a deliverable form; that is, field segments for MLC delivery. This step allows the setting of constraints for generating MLC segments, including minimum segment size. New beam deliverable doses are recalculated and the dose is then reoptimized using the same objectives as in the first stage by modulating the beam weights. Finally, dose is calculated. Figure 1 shows the overall methodology of the study. IMRT optimization was done with constraints for the PTV, rectum, and bladder. Table 1 shows the set of objective function parameters used for all MSS plans for each patient in this study. After optimization, deliverable MLC segments were calculated to achieve the ideal beamlet fluence. In this step, the MSS setting was changed by 1.0 cm, 1.5 cm, 2.0 cm, 2.2 cm, 2.5 cm, and 3.0 cm. The final dose was then calculated by a Fast Fourier Transform (FFT) convolution algorithm with a 2.0 mm grid size. The prescription dose for this study was selected as 70 Gy with the D95 prescription for the PTV. Analysis included the total number of segments and total MU; PTV homogeneity index (HI), defined as the ratio of PTV maximum dose to PTV minimum dose; V107 of PTV, the volume receiving 107% of the prescribed dose; and maximum rectal and bladder dose in various MSS plans. In addition, the relative proportion of subsegment areas was evaluated, with 'subsegment area' defined as follows: if there was one aperture in one segment, as in Fig. 2 (a) , we counted one set of 1-cm 2 subsegments; if there were five aper- tures in one segment, as in Fig. 2 (b) , we counted one set of 14-cm 2 subsegments and four sets of 1-cm 2 subsegments. Table 2 shows patient characteristics, with column 5 showing the number of total segments in the MSS 1.0 cm plan. In patient 1, who had an extremely large PTV, the IMRT beams contained 85 segments, while the number of total segments for the other patients ranged from 68 to 75. Column 6 of Table 1 shows the proportion of 1.0-cm 2 subsegments in the MSS 1.0 cm plan. In patient 1, about 18% of subsegments were 1.0 cm 2 .
Composite plan verification
Composite IMRT plan verification was performed using GafChromic-type EBT film (International Specialty Products, Wayne, NJ) and the I'mRT phantom (IBA Dosimetry GmbH, Schwarzenbruck, Germany). The verification plan of patient 1 was chosen because this had the highest proportion of 1.0 × 1.0 cm 2 subsegments with the MSS 1.0 cm plan (Table 2) , which is the most severe condition to assure dosimetric accuracy. Films were loaded into the phantom in the isocenter plane perpendicular to the beam axis. Composite fields with the MSS 1.0 cm, 1.5 cm, 2.0 cm, and 2.5 cm plans were irradiated.
A flatbed scanner (Epson Seiko Corporation, Nagano, Japan) was used to analyze films. Due to post-exposure density growth in films, many reports recommend that films be scanned at least 6 hours after irradiation. [13] [14] [15] We therefore scanned all irradiated films at least 12 hours after the completion of irradiation. Further, because flatbed scanners require correction for scanning light intensity in the lateral scan direction, 16, 17) we corrected these effects in software developed in-house. Calibration curves were obtained just before the composite plan verification at a 25 cGy increment. Dose distributions of XiO and the films were read into the software and compared by analyzing dose differences and DTA. Table 3 shows changes in the number of total segments and MU according to various MSS plans. As the MSS increased, the number of segments significantly decreased with those of the MSS 1.5 cm, 2.0 cm, 2.2 cm, 2.5 cm, and 3.0 cm plans being 7%, 14%, 20%, 30%, and 40% lower than that of the MSS 1.0 cm plan, respectively. As MSS increased, Abbreviation: PTV = planning target volume Fig. 2 . Examples of segment shapes. In the present study, the definition of subsegment in (a) was one set of 1-cm 2 subsegment, and in (b) was one set of 14-cm 2 and four sets of 1-cm 2 subsegments. Abbreviations: Pt = patient; GTV = gross tumor volume; CTV = clinical target volume; PTV = planning target volume; MSS = minimum segment size total MU significantly decreased, with those at an MSS of 1.5 cm, 2.0 cm, and 3.0 cm being 8%, 15%, 20%, 22%, and 25% less than that of the MSS 1.0 cm plan, respectively. Figure 3 shows the relative proportion of subsegment area according to various MSS plans. As MSS increased, the percentage of smaller segments in which segment area was below 7 cm 2 decreased. On the other hand, the percentage of larger segments with an area greater than 9 cm 2 increased. The percentage of subsegments less than or equal to 4 cm 2 at an MSS of 1.0 cm, 1.5 cm, 2.0 cm, 2.2 cm, 2.5 cm, and 3.0 cm was 22%, 12%, 6%, 5%, 1%, and 0%, respectively. In plans with an MSS of 2.0 cm or greater, more than 90% of subsegments were greater than 9 cm 2 . Figure 4 (a)-(f) shows the example of axial dose distribution in various MMS plans of patient 1. The PTV was covered by a 95% isodose line (yellow line) in all plans because D95 prescription for PTV was performed. Although a slight difference between the MSS 1.0 cm and 1.5 cm plans was observed, large area of high dose was observed as MSS increased. The area enclosed by the 115% isodose line was greater with the MSS 2.0 cm than with the MSS 1.5 cm plan.
RESULTS

Effects of MSS on IMRT beam parameters
Effects of MSS on planning quality
High-dose areas of more than 115% (orange) and 120% (dark yellow) of the prescribed dose were observed with the MSS 2.0 cm and 2.2 cm plans, and the 2.5 cm and 3.0 cm plans, respectively. Figure 5 shows the example of DVHs of various MSS plans in patient 1. Little difference was observed between the MSS 1.0 cm and 1.5 cm plans in PTV (Fig. 5 (a) ). However, the DVHs were degraded as MSS increased. With regard to the DVH of the rectum, low dose volume increased as the MSS decreased, whereas high dose volume increased as MSS increased (Fig. 5 (b) ). With regard to the DVH of the bladder, little difference was observed between the MSS 1.0 cm and 1.5 cm plans, as was also seen with the DVH of the PTV (Fig. 5 (c) ). DVHs of the PTV, rectum, and bladder were rapidly degraded with MSS plans greater than or equal to 2.0 cm compared with MSS 1.0 cm plan. Figure 6 (a) shows the HI of the PTV by MSS for the five patients. Average differences between the MSS 1.0 cm and 1.5 cm plans, and the 1.5 cm and 2.0 cm plans were within 0.1% and 9.6%, respectively. HI values were rapidly degraded in the MSS 2.2 cm plan and above, with differences between the 1.0 cm and 2.2 cm, 2.5 cm, and 3.0 cm plans of more than 15%, 32%, and 51%, respectively. With regard to V107 of PTV, the difference between MSS 1.0 cm and 1.5 cm was 2% (Fig. 6 (b) ). In contrast, V107 values of the MSS 2.0 cm or greater plans were more than 2.5-fold that of the MSS 1.0 cm plan. The same tendency was also observed with regard to maximum rectal and bladder doses. Although the differences between the MSS 1.0 cm and 1.5 cm or 2.0 cm plans were within 2.5%, these ratios rapidly increased at an MSS of 2.2 cm and greater, and with the MSS 2.5 cm plan were 1.11-and 1.28-fold that of the MSS 1.0 cm plan, respectively ( Fig. 6 (c), (d) ). The degree of increase in the ratio of these parameters appeared to correlate with a larger seminal vesicle volume. Table 3 summarizes these dosimetric results and statistical analyses according to various MSS settings. The difference in HI of PTV between the MSS 1.0 cm and 1.5 cm plans was within 0.5%, which was not statistically significant (p = 0.240). Although 9.6% difference for the five patients was observed between MSS 1.5 cm and 2.0 cm, this was not significant (p = 0.155), with only the difference between the MSS 2.2 cm and 2.5 cm plans being significant. With regard to the V107 of PTV, however, a significant difference was observed between MSS 1.5 cm and 2.0 cm (p < 0.05), whereas no significant difference was observed between MSS 1.0 cm and 1.5 cm. The same tendency was observed with regard to maximum rectal dose. For maximum bladder dose, no significant difference was observed between MSS 1.5 cm and 2.0 cm (p = 0.065). Figure 7 shows the results of composite verification of various MSS plans in patient 1. Regions in which the dose difference between the measured and calculated doses was within 5% are colored. The red regions indicate that the measured dose was larger than the planned dose, but that the dose difference was within ± 5%. On the other hand, the blue regions indicate that the measured dose was smaller than the planned dose, but that the dose difference was within ± 5%. The white regions indicate that the difference between the measured and planned dose was greater than ± 5%. Many such regions were observed with the MSS 1.0 cm plan ( Fig.  7 (a) ) in the PTV, whereas few were seen with the MSS 1.5 cm plan. The white regions in Fig. 7 (b) , (c) and (d) around the PTV show high-dose gradient regions in which DTA within 3 mm was confirmed.
Composite plan verification at various MSS plans
DISCUSSION
We investigated the optimum minimum segment size in two-step IMRT optimization with regard to both planning quality and dosimetric accuracy.
Several optimization methods are available in commercial treatment planning systems, including two-step optimization and direct-aperture optimization. [1] [2] [3] [4] [5] [6] Several studies have demonstrated the optimal minimum segment size for IMRT planning. 6, 9, 16) Worthy et al. reported that the minimum segment area setting in DMPO should be 8 cm 2 , taking into account both planning quality and treatment delivery time. 6) Lydon investigated the calculation accuracy of small segments using Pinanacle 3 and Varian linear accelerator 18) and demonstrated that segments of less than 1 cm in width should not be used for IMRT. Aspradakis et al. reported that a minimum segment size of less than 2 cm was not suitable for step and shoot IMRT, considering mechanical limitations such as beam output stability for low MU settings. 9) However, these latter two papers did not investigate the effect of minimum segment size on planning quality. To our knowledge, optimal segment size in two-step optimization with regard to both planning quality and dosimetric accuracy has not been investigated in detail.
In the present study, no significant change was seen between the MSS 1.0 cm and 1.5 cm plans with respect to DVHs of the PTV, bladder and rectum. In contrast, a significant change was seen between the MSS 1.5 cm and 2.0 cm plans for V107 of the PTV and maximum rectal dose, and planning quality rapidly deteriorated with MSS plans greater than 2.2 cm. Interestingly, the degree of degradation of HI or V107 of the PTV and maximum rectal and bladder dose tended to depend on seminal vesicle volume (Fig. 6) : as seminal vesicle volume increases, a larger part of the PTV involves the rectum. To compensate for regions overlapping the PTV and rectum, smaller segments were generated (data not shown). In such situations, a smaller MSS might provide better coverage of the PTV. On the other hand, the number of total segments and total MU in the MSS 1.5 cm plan were significantly decreased compared with the MSS 1.0 cm plan, indicating that treatment time with the MSS 1.5 cm plan may be shorter than with the 1.0 cm plan, during which intrafractional patient movement may occur. Therefore, with regard to planning quality, we concluded that the optimal minimum segment size setting was MSS 1.5 cm, but that more than 2.2 cm was clinically unacceptable. It also appeared that planning quality tended to be worse when seminal vesicle volume was large ( Fig. 6 (a), (b) ). In such cases, even MSS of 2.0 cm or greater should be avoided.
Compared to the traditional radiotherapy with fields > 4 × 4 cm 2 , small fields or segments used in IMRT can result in significant uncertainty in the accuracy of clinical dosimetry.
7)
Thus it becomes difficult to assure the accuracy of beam delivery. [7] [8] [9] [10] [11] To examine whether small MSS plans can accurately calculated and delivered, we next conducted composite plan verification for the MSS 1.0 cm, 1.5 cm, 2.0 cm and 2.5 cm plans using GafChromic-type EBT films. We used the plan of patient 1 because the proportion of 1 × 1 cm 2 subsegment with MSS 1.0 cm plan was the largest of the 5 patients, which is the severe condition in IMRT plan verification. In IMRT, a dose difference of 3% has been commonly used as a tolerance level. 19) Van Battum et al. estimated an uncertainty of at least 1.3% (1SD) for GafChromic-type EBT film dosimetry. 19) Our data revealed a 1.4% dose difference (1SD) between calculation by XiO and by film measurement in the flat region of a simple field profile (5.0 × 5.0 cm 2 ), which agreed with an ion chamber measurement within 0.5% (data not shown). In addition, there are other sources of dose uncertainties including film inhomogeneity which was found to be 1.1%. 20) We therefore set a tolerance level of 5% for dose difference analysis. Our data showed that the MSS 1.0 cm plan was not acceptable because the regions where the dose difference between calculated and measured dose was beyond 5% existed around PTV. On the other hand, the MSS 1.5 cm plan was acceptable because only few regions had a dose difference between the calculated and measured dose of more than 5%. Although dose distribution between the MSS 1.0 cm and 1.5 cm plans was similar (Fig. 4) , the proportion of segments was found to be different (Fig. 3) . In particular, the MSS 1.0 cm plan contained many smaller subsegments, such as 1.0 × 1.0 cm 2 . Previous study has shown that the calculation accuracy of off-axis 1.0 × 1.0 cm 2 was beyond 5% using Helax Collapsed Cone algorithm.
9) Therefore these subsegments might be related with discrepancies between the calculated and measured dose.
Although many issues in small field dosimetry remain, including beam modeling accuracy and output factors measurement technique, 7, 9, 21) our composite plan verification contains these components. We therefore concluded that the use of a 1.5 cm MMS setting is appropriate with regard to both planning quality and dosimetric accuracy.
Of note, MLC positioning within 0.6 mm in this study was assured by performing MLC positional calibration at least once a month and checking it weekly. In addition, we used segments of greater than 5 MU only, ensuring stable beam delivery and output. We also assured dose calculation accuracy down to a 1.5 × 1.5 cm field within the accuracy of 2% dose difference and a 2-mm DTA (data not shown).
With regard to more complicated IMRT, such as for head and neck cancer, the percentage of smaller segments would be larger. Although the results of this study are therefore relevant to prostate IMRT only, the process we used to determine minimum segment size would be useful in studies of other sites of IMRT.
In conclusion, the minimum segment size setting in IMRT optimization impacts dose distribution. Our data showed that an MSS 1.5 cm setting was suitable for prostate IMRT planning with regard to both planning quality and dosimetric accuracy. Although several papers have demonstrated that DMPO is a practical and preferable alternative to two-step optimization, 1, 6, 22) commercial treatment planning systems that use only two-step optimization remain available. Our findings could therefore be useful in determining or reviewing the validity of MSS settings in clinical practice.
